Moreover, data reported by Guo et al. [208] revealed that evaluation of the cellular p-eIF2α level may have a clinical application, since the level of p-eIF2α is significantly enhanced in breast cancer cells in comparison with peritumor tissue. This evidence concerns the gene EIF2A and breast cancer.